SOAT1 and mature T-cell and NK-cell non-Hodgkin lymphoma: PTCL patients (n = 19) with JAK/STAT mutations (cohort 1) exhibited clinical benefit rates (CBRs) approximately four times higher (53%) than those negative for biomarker expression (13% for cohort 3; n = 15) (122).